Lynparza: Regulatory decision in Japan for ovarian cancer (based on PAOLA trial) in H2 2020 (AstraZeneca) - Jul 30, 2020 - H1 2020 Results: Regulatory decision in China for BRCAm breast cancer in H2 2020
Japanese regulatory • Non-US regulatory • Breast Cancer • Oncology • Ovarian Cancer
|